natgillin/translations-raw huggingface dataset:
The safety and efficacy of NASONEX Nasal Spray has not been studied for use in the treatment of unilateral polyps, polyps associated with cystic fibrosis, or polyps that completely obstruct the nasal cavities. 
Nosni polipi Varnosti in učinkovitosti uporabe zdravila Nasonex pršilo za nos pri zdravljenju enostranskih polipov,
Seasonal Allergic Rhinitis and Perennial Rhinitis The safety and efficacy of NASONEX Nasal Spray in children under 3 years of age have not been established. 
Varnost in učinkovitost zdravila NASONEX pršilo za nos pri otrocih, mlajših od 3 let, nista bili dokazani.
swollen face, tongue or pharynx trouble swallowing hives wheezing or trouble breathing 
Bolezni dihal, prsnega koša in mediastinalnega prostora krvavitev iz nosu* krvavitev iz nosu vnetje nosne sluznice draženje nosne sluznice razjede nosne sluznice perforacija nosnega pretina
Always use Nasonex exactly as your doctor has told you. 
Med uporabo zdravila Nasonex se posvetujte z zdravnikom
NASONEX and associated names strength pharmaceutical form [See Annex I - To be completed nationally] 
IME ZDRAVILA Nasonex in povezana imena jakost farmacevtska oblika
If symptoms are not controlled after 5 to 6 weeks, the dose may be increased to two sprays in each nostril twice daily. 
Običajni začetni odmerek sta dva vpiha v vsako nosnico enkrat na dan. • Če po 5 do 6 tednih simptomi niso pod nadzorom, vam zdravnik odmerek lahko poveča na dva vpiha v vsako nosnico dvakrat na dan.
Repeat step 4 to inhale a second spray in the same nostril if applicable. 
Če morate skozi isto nosnico vdihniti še drugi vpih pršila, ponovite korak 4.
It is recommended that the height of children receiving long-term treatment with nasal corticosteroids is regularly monitored and if any changes are noted, their doctor should be notified. 
Pri otrocih, ki se dolgotrajno zdravijo z nazalnimi kortikosteroidi, je priporočljivo redno nadzirati telesno višino.
Cleaning your nasal spray 
Čiščenje pršila za nos
You should wait until the infection is resolved before you start using the nasal spray. 
V tem primeru morate, preden začnete uporabljati pršilo za nos, počakati, da se okužba pozdravi.
NASONEX Nasal Spray is indicated for use in adults and children 3 years of age and older to treat the symptoms of seasonal allergic or perennial rhinitis. 
Zdravilo NASONEX pršilo za nos je indicirano za uporabo pri odraslih in otrocih, starih 3 leta ali več,
4.7 Effects on ability to drive and use machines 
4.7 Vpliv na sposobnost vožnje in upravljanja s stroji Vpliv zdravila Nasonex pršilo za nos na sposobnost vožnje in upravljanja s stroji ni znan.
Treatment of Hayfever and Perennial Rhinitis 
Druga zdravila in zdravilo Nasonex
Talk to your doctor or pharmacist before using Nasonex if you have or have ever had tuberculosis. 
Pred začetkom uporabe zdravila Nasonex se posvetujte z zdravnikom ali farmacevtom
However, some people, after using Nasonex or other corticosteroid nasal sprays, may find that they suffer from: 
Pri nekaterih bolnikih pa se pri uporabi zdravila Nasonex ali drugih kortikosteroidnih pršil za nos lahko pojavi kateri od naslednjih neželenih učinkov: Pogosti neželeni učinki (pojavijo se lahko pri največ 1 od 10 bolnikov):
Throat irritation* 
• glavobol • kihanje
Dose reduction is recommended following control of symptoms. 
Ko so simptomi pod nadzorom, je odmerek priporočljivo zmanjšati.
if you have persistent irritation to the nose or throat. 
• če imate težave z neprestanim draženjem nosu ali žrela.
Infections and infestations 
• okužba dihal
Dispersable cellulose (microcrystalline cellulose and carmellose sodium) Glycerol 
6.1 Seznam pomožnih snovi disperzibilna celuloza (mikrokristalna celuloza in natrijev karmelozat) glicerol natrijev citrat citronska kislina monohidrat polisorbat 80 benzalkonijev klorid prečiščena voda
This leaflet was last approved in [To be completed nationally] 
[glejte Prilogo I - izpolni država članica] Navodilo je bilo nazadnje revidirano dne
It has been used in medicines for several decades. 
V zdravilih se uporablja že več desetletij.
It is available as modified-release tablets (5 mg and 20 mg). 
Na voljo je v obliki tablet s prirejenim sproščanjem (5 mg in 20 mg).
The European Commission granted a marketing authorisation valid throughout the European Union for Plenadren on 3 November 2011. 
Evropska komisija je dovoljenje za promet z zdravilom Plenadren, veljavno po vsej Evropski uniji, izdala 3. novembra 2011.
What measures are being taken to ensure the safe and effective use of Plenadren? 
Kateri ukrepi se izvajajo za zagotovitev varne in učinkovite uporabe zdravila Plenadren?
Other information about Plenadren 
Druge informacije o zdravilu Plenadren
In situations of excessive physical or mental stress or illness, patients may need further doses of hydrocortisone. 
Pri izjemnem fizičnem ali psihičnem stresu ali bolezni bo bolnik morda potreboval dodatne odmerke hidrokortizona.
Treatment may need to be individually adjusted according to how the patient responds. 
Zdravljenje je treba prilagoditi posamezniku glede na njegov odziv.
Symptoms include weight loss, muscle weakness, fatigue, low blood pressure, and sometimes darkening of the skin. 
Med simptomi so izguba telesne mase, mišična oslabelost, utrujenost, nizek krvni tlak in včasih potemnenje kože.
This is a summary of the European public assessment report (EPAR) for Plenadren. 
To je povzetek evropskega javnega poročila o oceni zdravila (EPAR) za zdravilo Plenadren.
The CHMP concluded that the benefits of Plenadren were greater than its risks and recommended that it be granted marketing authorisation. 
Odbor je zaključil, da so koristi zdravila Plenadren večje od z njim povezanih tveganj, in priporočil, da se zanj izda dovoljenje za promet.
Adrenal insufficiency (including primary insufficiency or Addison's disease) is a condition where the adrenal glands (located just above the kidneys) do not produce enough of a steroid hormone called cortisol (also known as the stress hormone because it is released in response to stress). 
Adrenalna insuficienca (vključno s primarno insuficienco ali Addisonovo boleznijo) je obolenje, pri katerem nadledvične žleze (ki so neposredno nad ledvicami) ne proizvajajo dovolj steroidnega hormona, imenovanega kortizol (znanega tudi kot stresni hormon, saj se izloči kot odgovor na stres).
Why is Plenadren approved? 
Zakaj je bilo zdravilo Plenadren odobreno?
What is Plenadren and what is it used for? 
Kaj je zdravilo Plenadren in za kaj se uporablja?
The study looked at the levels of cortisol in the patients' blood during a 24-hour period following three months of treatment. 
V študiji so opazovali ravni kortizola v bolnikovi krvi v 24 urah po treh mesecih zdravljenja.
It is taken early in the morning to mimic the fact that in healthy people the blood level of cortisol increases early in the morning. 
Jemlje se zgodaj zjutraj, kar ustreza dejstvu, da se ravni kortizola v krvi pri zdravih ljudeh zgodaj zjutraj povišajo.
It is not intended to provide practical advice on how to use Plenadren. 
Povzetek ni namenjen zagotavljanju praktičnih nasvetov o njegovi uporabi.
This may be given as Plenadren tablets twice or three times daily or as conventional immediate-release tablets or injections, either alone or in combination with Plenadren. 
Ti se lahko dajo v obliki dodatnih tablet zdravila Plenadren dvakrat ali trikrat na dan ali konvencionalnih tablet s takojšnjim sproščanjem ali injekcij, samostojno ali v kombinaciji z zdravilom Plenadren.
The summary of the opinion of the Committee for Orphan Medicinal Products for Plenadren can be found on the Agency's website: ema.europa.eu/Find medicine/Human medicines/Rare disease designations. 
Povzetek mnenja Odbora za zdravila sirote o zdravilu Plenadren je na voljo na spletni strani agencije: ema.europa.eu/Find medicine/Human medicines/Rare disease designations.
What are the risks associated with Plenadren? 
Kakšna tveganja so povezana z zdravilom Plenadren?
Adrenal insufficiency can require life-long treatment to replace the missing cortisol. 
Adrenalna insuficienca lahko zahteva doživljenjsko zdravljenje, da se nadomešča manjkajoči kortizol.
What benefits of Plenadren have been shown in studies? 
Kakšne koristi je zdravilo Plenadren izkazalo v študijah?
The effects of Plenadren were investigated in one main study involving 64 patients with adrenal insufficiency. 
Koristi zdravila Plenadren so raziskovali v eni glavni študiji, v katero je bilo vključenih 64 bolnikov z adrenalno insuficienco.
For more information about treatment with Plenadren, read the package leaflet (also part of the EPAR) or contact your doctor or pharmacist. 
Za več informacij o zdravljenju z zdravilom Plenadren preberite navodilo za uporabo (ki je prav tako del EPAR) ali se posvetujte z zdravnikom ali farmacevtom.
Because the number of patients with adrenal insufficiency is low, the disease is considered ‘rare', and Plenadren was designated an ‘orphan medicine' (a medicine used in rare diseases) on 22 May 2006. 
Ker je bolnikov s to boleznijo malo, velja ta bolezen za redko, zato je bilo zdravilo Plendaren 22. maja 2006 določeno kot „zdravilo sirota“ (zdravilo za zdravljenje redkih bolezni).
Recommendations and precautions to be followed by healthcare professionals and patients for the safe and effective use of Plenadren have been included in the summary of product characteristics and the package leaflet. 
Priporočila in varnostni ukrepi, ki jih morajo za varno in učinkovito uporabo tega zdravila upoštevati zdravstveni delavci in bolniki, so vključeni v povzetek glavnih značilnosti zdravila in navodilo za njegovo uporabo.
The overall amount of cortisol absorbed into the blood was around 20% lower in patients taking Plenadren compared with patients taking conventional hydrocortisone treatment. 
Celotna količina kortizola, absorbiranega v krvi, je bila približno 20 % nižja pri bolnikih, ki so jemali zdravilo Plenadren, v primerjavi z bolniki, ki so prejemali konvencionalno zdravljenje s hidrokortizonom.
Plenadren, given once per day, was compared with conventional hydrocortisone treatment, which is given three times per day. 
Zdravilo Plenadren, ki se daje enkrat na dan, so primerjali s konvencionalnim hidrokortizonskim zdravljenjem, ki se daje trikrat na dan.
The most common side effects with Plenadren (seen in more than 1 patient in 10) are fatigue (tiredness), diarrhoea, vertigo (feeling dizzy) and headache. 
Najpogostejši neželeni učinki zdravila Plenadren (opaženi pri več kot 1 bolniku od 10) so utrujenost, driska, omotica in glavobol.
Plenadren is a medicine used to treat adrenal insufficiency in adults. 
Plenadren je zdravilo, ki se uporablja za zdravljenje adrenalne insuficience pri odraslih.
The full EPAR for Plenadren can be found on the Agency's website: ema.europa.eu/Find medicine/Human medicines/European Public Assessment Reports. 
Celotno evropsko javno poročilo o oceni zdravila (EPAR) za zdravilo Plenadren je na voljo na spletni strani agencije: ema.europa.eu/Find medicine/Human medicines/European Public Assessment Reports.
For practical information about using Plenadren, patients should read the package leaflet or contact their doctor or pharmacist. 
Za praktične informacije o uporabi zdravila Plenadren naj bolniki preberejo navodilo za uporabo ali se posvetujejo z zdravnikom ali farmacevtom.
For the full list of all side effects and restrictions with Plenadren, see the package leaflet. 
Za celoten seznam neželenih učinkov in omejitev pri uporabi zdravila Plenadren glejte navodilo za uporabo.
The active substance in Plenadren, hydrocortisone, is the pharmaceutical form of cortisol, the main steroid hormone secreted by the adrenal gland. 
Zdravilna učinkovina v zdravilu Plenadren, hidrokortizon, je farmacevtska oblika kortizola, tj. glavnega steroidnega hormona, ki ga izloča nadledvična žleza.
Hydrocortisone replaces the natural cortisol that is missing in patients with adrenal insufficiency. 
Hidrokortizon nadomešča naravni kortizol, ki ga primanjkuje ljudem z adrenalno insuficienco.
In patients taking Plenadren the cortisol levels achieved were considered to be satisfactory for patients with adrenal insufficiency. 
Pri bolnikih, ki so jemali zdravilo Plenadren, so bile dosežene ravni kortizola ocenjene kot zadovoljive za bolnike z adrenalno insuficienco.
Plenadren contains the active substance hydrocortisone. 
Zdravilo Plenadren vsebuje zdravilno učinkovino hidrokortizon.
How does Plenadren work? 
Kako zdravilo Plenadren deluje?
The Agency's Committee for Medicinal Products for Human Use (CHMP) noted that Plenadren achieved satisfactory levels of cortisol during the treatment of patients with adrenal insufficiency. 
Odbor za zdravila za uporabo v humani medicini (CHMP) pri agenciji je menil, da so pri zdravljenju bolnikov z adrenalno insuficienco ravni kortizola, dosežene z zdravilom Plenadren, zadovoljive.
How is Plenadren used? 
Kako se zdravilo Plenadren uporablja?
The usual daily dose ranges from 20 to 30 mg, once per day early in the morning; tablets should be swallowed whole with a glass of water at least 30 minutes before food. 
Običajni odmerek je od 20 do 30 mg enkrat na dan zgodaj zjutraj.
Because it is available as a modified-release tablet, Plenadren releases hydrocortisone over a longer period of time allowing for a once-daily dosing. 
Ker je zdravilo Plenadren na voljo v obliki tablet s prirejenim sproščanjem, se hidrokortizol sprošča dlje, kar omogoča jemanje zdravila samo enkrat na dan.
Although once daily dosing comes with a risk of cortisol levels being too low in the afternoon, this can be managed by adding further doses of hydrocortisone if needed. 
Prav tako je ugotovil, da je zdravilo priročno zaradi odmerjanja enkrat na dan. Odmerki enkrat na dan sicer lahko pomenijo tveganje za prenizke ravni kortizola v popoldanskih urah, kar pa je mogoče uravnati z dodatnimi odmerki hidrokortizola po potrebi.
Plenadren can only be obtained with a prescription. 
Predpisovanje in izdaja zdravila je le na recept.
Ristfor is taken twice a day. 
Zdravilo Ristfor se jemlje dvakrat na dan.
What measures are being taken to ensure the safe and effective use of Ristfor? 
Kateri ukrepi se izvajajo za zagotovitev varne in učinkovite uporabe zdravila Ristfor?
The full EPAR for Ristfor can be found on the Agency's website: ema.europa.eu/Find medicine/Human medicines/European public assessment reports. 
Celotno evropsko javno poročilo o oceni zdravila (EPAR) za zdravilo Ristfor je na voljo na spletni strani agencije: ema.europa.eu/Find medicine/Human medicines/European public assessment reports.
The European Commission granted a marketing authorisation valid throughout the EU for Ristfor on 15 March 2010. 
Evropska komisija je dovoljenje za promet z zdravilom Ristfor, veljavno po vsej Evropski uniji, izdala 15. marca 2010.
Sitagliptin has been authorised in the European Union (EU) as Januvia and Xelevia since 2007 and as Tesavel since 2008. 
V Evropski uniji (EU) je bil odobren pod imenoma Januvia in Xelevia od leta 2007 in pod imenom Tesavel od leta 2008.
The results of three further studies were used to support the use of Ristfor. 
Rezultati treh nadaljnjih študij so bili uporabljeni v podporo uporabi zdravila Ristfor.
What benefit has Ristfor shown during the studies? 
Kakšne koristi je zdravilo Ristfor izkazalo med študijami?
Ristfor sitagliptin / metformin hydrochloride 
Ristfor sitagliptin/metforminijev klorid
Sitagliptin is a dipeptidyl-peptidase-4 (DPP 4) inhibitor. 
Sitagliptin je zaviralec dipeptidil-peptidaze-4 (DPP 4).
The strength of tablet to use depends on the dose of the other diabetes medicines that the patient was taking before. 
Jakost tablete, ki jo je treba uporabiti, je odvisna od odmerka drugih zdravil za sladkorno bolezen, ki ga je bolnik jemal prej.
This authorisation was based on the authorisation granted to Janumet in 2008 (‘informed consent'). 
Izdaja tega dovoljenja je temeljila na dovoljenju za promet za zdravilo Janumet, ki je bilo izdano leta 2008 (uporaba dokumentacije s soglasjem).
For more information about treatment with Ristfor, read the package leaflet (also part of the EPAR) or contact your doctor or pharmacist. 
Za več informacij o zdravljenju z zdravilom Ristfor preberite navodilo za uporabo (ki je prav tako del EPAR) ali se posvetujte z zdravnikom ali farmacevtom.
The CHMP decided that Ristfor's benefits are greater than its risks and recommended that it be given marketing authorisation. 
CHMP je zaključil, da so koristi zdravila Ristfor večje od z njim povezanih tveganj, in priporočil, da se zanj izda dovoljenje za promet.
A risk management plan has been developed to ensure that Ristfor is used as safely as possible. 
Za zagotovitev čim varnejše uporabe zdravila Ristfor je bil pripravljen načrt obvladovanja tveganj.
It is used in addition to diet and exercise in the following ways: 
Uporablja se kot dodatek k prehrani in telesni vadbi, in sicer:
It explains how the Committee for Medicinal Products for Human Use (CHMP) assessed the medicine to reach its opinion in favour of granting a marketing authorisation and its recommendations on the conditions of use for Ristfor. 
Pojasnjuje, kako je Odbor za zdravila za uporabo v humani medicini (CHMP) ocenil to zdravilo, na podlagi česar je oblikoval mnenje za izdajo dovoljenja za promet z njim in priporočila glede pogojev njegove uporabe.
Other information about Ristfor: 
Druge informacije o zdravilu Ristfor:
Based on this plan, safety information has been included in the summary of product characteristics and the package leaflet for Ristfor, including the appropriate precautions to be followed by healthcare professionals and patients. 
V skladu s tem načrtom so bile v povzetek glavnih značilnosti zdravila in navodilo za uporabo za to zdravilo vključene informacije o varnosti, vključno s previdnostnimi ukrepi, ki jih morajo upoštevati zdravstveni delavci in bolniki.
It is available as tablets (50 mg sitagliptin and 850 mg metformin hydrochloride; 50 mg sitagliptin and 1,000 mg metformin hydrochloride). 
Na voljo je v obliki tablet (50 mg sitagliptina/850 mg metforminijevega klorida in 50 mg sitaglipina/1 000 mg metforminijevega klorida).
Why has Ristfor been approved? 
Zakaj je bilo zdravilo Ristfor odobreno?
What is the risk associated with Ristfor? 
Kakšna tveganja so povezana z zdravilom Ristfor?
Ristfor must not be used in patients who have diabetic ketoacidosis or pre coma (dangerous conditions that can occur in diabetes), problems with the kidneys or liver, conditions that may affect the kidneys, or a disease that causes a reduced supply of oxygen to the tissues such as failure of the heart or lungs or a recent heart attack. 
Zdravilo Ristfor se ne sme uporabljati pri bolnikih, ki imajo diabetično ketoacidozo, predkomo (nevarno stanje, ki se lahko pojavi pri sladkorni bolezni), težave z ledvicami ali jetri, obolenja, ki lahko prizadenejo ledvice, ali obolenja, ki povzročajo zmanjšano oskrbo tkiv s kisikom, kot so srčno popuščanje, težave s pljuči ali nedavni srčni napad.
The company presented the results of three studies of Januvia/Xelevia to support the use of Ristfor in patients who were not satisfactorily controlled on their existing metformin treatment. 
Družba je predstavila rezultate treh študij z zdraviloma Januvia/Xelevia v podporo uporabi zdravila Ristfor pri bolnikih, pri katerih obstoječe zdravljenje z metforminom ni zadostno za nadzor bolezni.
This document is a summary of the European Public Assessment Report (EPAR) for Ristfor. 
Ta dokument je povzetek evropskega javnega poročila o oceni zdravila (EPAR) za zdravilo Ristfor.
• in combination with a sulphonylurea, a PPAR-gamma agonist such as a thiazolidinedione, or insulin 
• v kombinaciji s sulfonilsečnino, agonistom PPAR gama, kot je tiazolidinedion, ali insulinom (tj.
The effectiveness of adding sitagliptin to metformin was similar to that of adding glipizide. 
Učinkovitost dodajanja sitagliptina metforminu je bila podobna kot pri dodajanju glipizida.
Ristfor should be taken with food to avoid any stomach problems caused by metformin. 
Zdravilo Ristfor je treba jemati s hrano, da se preprečijo želodčne težave, ki jih povzroča metformin.
Ristfor was more effective than metformin alone. 
Zdravilo Ristfor je bilo učinkovitejše od metformina samega.
Sitagliptin does not work when the blood glucose is low. 
Sitagliptin ne deluje, če je raven glukoze v krvi nizka.
Metformin works mainly by inhibiting glucose production and reducing its absorption in the gut. 
Metformin deluje predvsem z zaviranjem tvorbe glukoze in zmanjševanjem njene absorpcije v črevesju.
The company carried out additional studies to show that the active substances in Ristfor are absorbed by the body in the same way as the two medicines given separately. 
Družba je opravila še nadaljnje študije, da bi dokazala, da telo zdravilni učinkovini zdravila Ristfor absorbira na enak način, kot če sta vzeti v obliki ločenih zdravil.
If Ristfor is taken with a sulphonylurea or insulin, the dose of the sulphonylurea or insulin may need to be lowered, to avoid hypoglycaemia (low blood sugar levels). 
Če se zdravilo Ristfor jemlje skupaj s sulfonilsečnino ali insulinom, bo morda treba odmerek sulfonilsečnine ali insulina zmanjšati, da ne bi prišlo do hipoglikemije (nizkih ravni sladkorja v krvi).
As a result of the action of both active substances, blood glucose levels are reduced and this helps to control type 2 diabetes. 
Kot posledica delovanja obeh zdravilnih učinkovin se raven glukoze v krvi zniža, to pa prispeva k nadzoru sladkorne bolezni tipa 2.
Serious side effects reported with Ristfor include pancreatitis (inflammation of the pancreas) and hypersensitivity (allergic reactions). 
Med resnimi neželenimi učinki, o katerih so poročali pri uporabi zdravila Ristfor sta pankreatitis (vnetje trebušne slinavke) in preobčutljivostne (alergijske) reakcije.
Ristfor is used in patients with type 2 diabetes to improve the control of blood glucose (sugar) levels. 
Zdravilo Ristfor se uporablja za zdravljenje bolnikov s sladkorno boleznijo tipa 2 za izboljšanje nadzora nad ravnjo glukoze (sladkorja) v krvi.
Ristfor is a diabetes medicine that contains two active substances, sitagliptin and metformin hydrochloride. 
Ristfor je zdravilo, ki vsebuje dve zdravilni učinkovini, sitagliptin in metforminijev klorid.
In the first of the three further studies, Ristfor was more effective than metformin or sitagliptin alone. 
V prvi od treh dodatnih študij je bilo zdravilo Ristfor učinkovitejše od metformina ali sitagliptina samega.
(other types of diabetes medicine) in patients who are not satisfactorily controlled on this medicine and metformin. 
drugimi vrstami zdravil za sladkorno bolezen) pri bolnikih, pri katerih bolezen ni zadostno nadzorovana s kombinacijo enega od teh zdravil in metformina.
The second included 278 patients who were not satisfactorily controlled on the combination of metformin and rosiglitazone (a PPAR-gamma agonist) and compared the effects of adding sitagliptin or placebo. 
V drugo je bilo vključenih 278 bolnikov, pri katerih nadzor s kombinacijo metformina in rosiglitazona (agonista PPAR gama) ni bil zadosten, v njej pa so primerjali učinke dodajanja sitagliptina ali placeba.
Hypoglycaemia has been reported in combination with a sulphonylurea in 13.8% of patients and with insulin in 10.9% of patients. 
V kombinaciji s sulfonilsečnino je prišlo do hipoglikemije pri 13,8 % bolnikov, v kombinaciji z insulinom pa pri 10,9 % bolnikov.
The first included 1,091 patients who were not satisfactorily controlled on diet and exercise alone and compared the effect of Ristfor with that of metformin or sitagliptin alone. 
V prvo je bilo vključenih 1 091 bolnikov, pri katerih zadosten nadzor ni bil dosežen zgolj z dieto in telesno vadbo, v njej pa so primerjali učinke zdravila Ristfor z učinki metformina ali sitagliptina, uporabljenih samostojno.
Two of the studies looked at sitagliptin as an add-on to metformin: the first compared it with placebo (a dummy treatment) in 701 patients, and the second compared it with glipizide (a sulphonylurea) in 1,172 patients. 
V dveh študijah so proučevali sitagliptin kot dodatek metforminu: v prvi so ga pri 701 bolniku primerjali s placebom (zdravilom brez zdravilne učinkovine), v drugi pa z glipizidom (sulfonilsečnino) pri 1 172 bolnikih.